Pays
Auteurs
Exploration
Accueil
Racine
Exploration
Accueil
Racine

Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Eléments de l'association

Portugal85
Joaquim J. Ferreira14
Portugal Sauf Joaquim J. Ferreira" 73
Joaquim J. Ferreira Sauf Portugal" 2
Portugal Et Joaquim J. Ferreira 12
Portugal Ou Joaquim J. Ferreira 87
Corpus10303
\n\n\n\n \n

List of bibliographic references

Number of relevant bibliographic references: 12.
Ident.Authors (with country if any)Title
000058 Sofia Reimão [Portugal] ; Patrícia Pita Lobo [Portugal] ; Dulce Neutel [Portugal] ; Leonor Correia Guedes [Portugal] ; Miguel Coelho [Portugal] ; Mário M. Rosa [Portugal] ; Pedro Azevedo [Portugal] ; Joana Ferreira [Portugal] ; Daisy Abreu [Portugal] ; Nilza Gonçalves [Portugal] ; Rita G. Nunes [Portugal] ; Jorge Campos [Portugal] ; Joaquim J. Ferreira [Portugal]Substantia nigra neuromelanin-MR imaging differentiates essential tremor from Parkinson's disease.
000148 Olivier Rascol [France] ; Santiago Perez-Lloret ; Joaquim J. Ferreira [Portugal]New treatments for levodopa-induced motor complications.
000243 Joaquim J. Ferreira [Portugal] ; Anne Rosser [Royaume-Uni] ; David Craufurd [Royaume-Uni] ; Ferdinando Squitieri [Italie] ; Nicholas Mallard [États-Unis] ; Bernhard Landwehrmeyer [Allemagne]Ethyl-eicosapentaenoic acid treatment in Huntington's disease: A placebo-controlled clinical trial.
001355 Christopher G. Goetz [États-Unis] ; Glenn T. Stebbins [États-Unis] ; Ad Theeuwes [Pays-Bas] ; Fabrizio Stocchi [Italie] ; Joaquim J. Ferreira [Portugal] ; Serge Van De Witte [Pays-Bas] ; Juliana Bronzova [Pays-Bas]Temporal stability of the Unified Dyskinesia Rating Scale
001641 Tiago Teodoro [Portugal] ; Daniela Pires [Portugal] ; Mário M. Rosa [Portugal] ; Miguel Coelho [Portugal] ; Cristina Sampaio [Portugal] ; Joaquim J. Ferreira [Portugal]Has “levodopa‐induced neuropathy” been reported in Parkinson's disease clinical trials?
001A05 Joaquim J. Ferreira [Portugal] ; Dulce Neutel [Portugal] ; Tiago Mestre [Portugal] ; Miguel Coelho [Portugal] ; Mário M. Rosa [Portugal] ; Olivier Rascol [France] ; Cristina Sampaio [Portugal]Skin cancer and Parkinson's disease
001A94 Mário Miguel Rosa [Portugal] ; Joaquim J. Ferreira [Portugal] ; Miguel Coelho [Portugal] ; Rita Freire [Portugal] ; Cristina Sampaio [Portugal]Prescribing patterns of antiparkinsonian agents in Europe
001C50 Elan D. Louis [États-Unis] ; Joaquim J. Ferreira [Portugal]How common is the most common adult movement disorder? Update on the worldwide prevalence of essential tremor
002479 Tiago Mestre [Portugal] ; Joaquim J. Ferreira [Portugal] ; Samay Jain [États-Unis]A multimodal approach to physical therapy in Parkinson's disease: Optimizing strategies
002E16 Joaquim J. Ferreira [Portugal, Pays-Bas] ; Leonor Correia Guedes [Portugal] ; Mário Miguel Rosa [Portugal] ; Miguel Coelho [Portugal] ; Marina Van Doeselaar [Pays-Bas] ; Dorothea Schweiger [Pays-Bas] ; Alessio Di Fonzo [Pays-Bas] ; Ben A. Oostra [Pays-Bas] ; Cristina Sampaio [Portugal] ; Vincenzo Bonifati [Pays-Bas]High prevalence of LRRK2 mutations in familial and sporadic Parkinson's disease in Portugal
003D72 Cristina Sampaio [Portugal] ; João Costa [Portugal] ; Joaquim J. Ferreira [Portugal]Clinical comparability of marketed formulations of botulinum toxin
005370 Sampaio ; Joaquim J. Ferreira ; Fernanda Sim Es [Portugal] ; Maria J. Rosas [Portugal] ; Marina Magalhães [Portugal] ; Ana P. Correia [Portugal] ; Ant Nio Bastos-Lima [Portugal] ; Rairnundo Martins [Portugal] ; Alexandre Castro-CaldasDYSBOT: A single‐blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A—Dysport and Botox—assuming a ratio of 4:1
Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024